# Ke Wang

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ke-wang/

## Facts

| Field | Value |
| --- | --- |
| Citations | 10,439 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 50 |
| i10-index | 201 |
| Last Known Institution | Zhejiang Chinese Medical University |
| OpenAlex ID | https://openalex.org/A5100360112 |
| ORCID iD | 0000-0002-2824-1047 |
| Works | 462 |

## Researcher papers

- [Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study](https://scholariq.org/papers/clinical-characteristics-of-fatal-and-recovered-cases-of-coronavirus-disease/)
- [γδT17 Cells Promote the Accumulation and Expansion of Myeloid-Derived Suppressor Cells in Human Colorectal Cancer](https://scholariq.org/papers/t17-cells-promote-the-accumulation-and-expansion-of-myeloid-derived-suppressor/)
- [Diagnostic accuracy of adenosine deaminase in tuberculous pleurisy: A meta-analysis](https://scholariq.org/papers/diagnostic-accuracy-of-adenosine-deaminase-in-tuberculous-pleurisy-a-meta/)
- [Cold but not sympathomimetics activates human brown adipose tissue in vivo](https://scholariq.org/papers/cold-but-not-sympathomimetics-activates-human-brown-adipose-tissue-in-vivo/)
- [The experience of high-flow nasal cannula in hospitalized patients with 2019 novel coronavirus-infected pneumonia in two hospitals of Chongqing, China](https://scholariq.org/papers/the-experience-of-high-flow-nasal-cannula-in-hospitalized-patients-with-2019/)
- [Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial](https://scholariq.org/papers/sintilimab-plus-bevacizumab-biosimilar-ibi305-and-chemotherapy-for-patients-with/)
- [Plasticity of cancer cell invasion: Patterns and mechanisms](https://scholariq.org/papers/plasticity-of-cancer-cell-invasion-patterns-and-mechanisms/)
- [Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial](https://scholariq.org/papers/sintilimab-plus-chemotherapy-for-patients-with-egfr-mutated-non-squamous-non/)
- [Accuracy of BAL Galactomannan in Diagnosing Invasive Aspergillosis](https://scholariq.org/papers/accuracy-of-bal-galactomannan-in-diagnosing-invasive-aspergillosis/)
- [Meplazumab treats COVID-19 pneumonia: an open-labelled, concurrent controlled add-on clinical trial](https://scholariq.org/papers/meplazumab-treats-covid-19-pneumonia-an-open-labelled-concurrent-controlled-add/)
- [Electroacupuncture Reduces Duration of Postoperative Ileus After Laparoscopic Gastrectomy for Gastric Cancer: A Multicenter Randomized Trial](https://scholariq.org/papers/electroacupuncture-reduces-duration-of-postoperative-ileus-after-laparoscopic/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Chronic Obstructive Pulmonary Disease (COPD) Research](https://scholariq.org/topics/chronic-obstructive-pulmonary-disease-copd-research/)
- [Respiratory Support and Mechanisms](https://scholariq.org/topics/respiratory-support-and-mechanisms/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Zhejiang Chinese Medical University](https://scholariq.org/institutions/zhejiang-chinese-medical-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.